Topical Antiperspirant for Hand-Foot Syndrome

• Status: Completed
• Trial end date: 2007-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The objectives of this study are to evaluate the effectiveness of an antiperspirant in preventing or attenuating the severity of palmer-plantar erythrodysesthesia associated with the Food and Drug Administration (FDA)-approved doses of capecitabine. The hypothesis is that cytotoxic compounds in sweat will be prevented from being deposited in the skin and causing chronic toxicity.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Wisconsin, Madison

Criteria

Inclusion Criteria:

• Has not previously received a regimen that includes 5-fluorouracil

• > 18 years old

• No known allergy or intolerance to Ban Unscented Roll-On Antiperspirant

Exclusion Criteria:

• < 18 years of age